Automated Prescription Medication Safety: Xact Labs Receives Groundbreaking Patent

TWINSBURG, Ohio, July 14, 2025 /PRNewswire/ — Xact Laboratories, a Biotech innovator in evidence-based medication guidance, has received a landmark United States Patent No.: US 12,354,724 B2, issued July 8, 2025, that will revolutionize pharmacogenomic and genetic efficacy data exchange. This milestone establishes Xact Laboratories’ intellectual property rights over genetic testing data transmitted to pharmacy systems or provider electronic networks- which is a critical step toward establishing pharmacogenomics (PGx) as standard of care.

“The issuance of this patent, marks a pivotal moment for Xact Laboratories and the future of genetic efficacy testing and PGx-guided treatment decisions,” said Rob Todd, Cofounder of Xact Laboratories.

Non-optimized medication therapy has been identified as a major driver of preventable healthcare costs and adverse outcomes—estimated at $528 billion annually and contributing to hundreds of thousands of avoidable deaths each year, according to peer-reviewed research and national pharmacy studies. Xact’s model addresses this avoidable outcome by enabling automated, real-time exchange of PGx requests and contraindication checks prior to a medication being dispensed. This patented process operates seamlessly within the existing native workflows of both pharmacy and provider ecosystems, leveraging Xact’s API and AI-enhanced algorithms to support every prescription decision for a participating member.

Xact Laboratories has created a universal PGx “clearinghouse”, a standardized, secure system for genetic efficacy data exchange. This platform addresses two longstanding barriers to personalized medicine:

1. Streamlining patient testing for payer-identified populations; and
2. Delivering real-time, actionable insights to prescribers to inform safe and effective treatment.

Implementation of Xact’ model delivers valuable benefits for payers, providers, and patients alike, including:

• Seamless Continuity of Care across All Providers
• Reduction in Total Medical Spend
• Strong ROI
• Higher STAR & HEDIS Ratings
• Improvement in Member Satisfaction Scores

This patent represents a major advancement in personalized medicine. Xact Laboratories is standardizing secure genetic data sharing to make healthcare more precise, efficient, and accessible to all. The company’s commitment to innovation is driving the transformation of healthcare while democratizing personalized medicine for all.

About Xact Laboratories

Xact Laboratories is a leader in pharmacogenomic testing and genetic efficacy data automation. With a commitment to advancing healthcare through integrated precision medicine, Xact Laboratories empowers healthcare providers and patients with a personalized approach to optimize medication safety and efficacy. 

CONTACT: Rob Todd
rtodd@xactlaboratories.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/automated-prescription-medication-safety-xact-labs-receives-groundbreaking-patent-302503016.html

SOURCE Xact Laboratories